Quantitative Concept
Novo Nordisk’s Ozempic Expected to Face Medicare Price Negotiations in 2025
Ozempic, Medicare, price negotiations, Novo Nordisk, diabetes medication, Inflation Reduction Act
Novo Nordisk CEO Faces Senate Scrutiny Over High Prices of Ozempic and Wegovy
Novo Nordisk, Senate Hearing, Ozempic, Wegovy, Drug Prices, Pharmacy Benefit Managers (PBMs), Insurance Coverage, Healthcare System
Appeals Court Revives PhRMA’s Challenge to IRA’s Medicare Drug Price Negotiation Program
PhRMA, Inflation Reduction Act, Medicare Drug Price Negotiation Program, Fifth Circuit Court of Appeals, drug pricing, healthcare litigation
Bristol Myers Squibb Continues Layoffs, Cutting 79 More Jobs in New Jersey Amid $1.5B Cost Reduction Effort
Bristol Myers Squibb, layoffs, New Jersey, cost reduction, pharmaceutical industry
Theratechnologies Warns of Temporary Supply Disruption for EGRIFTA SV in Early 2025 Due to Third-Party Facility Shutdown
Theratechnologies, EGRIFTA SV, supply disruption, third-party facility shutdown, HIV drug, 2025
Cigna Challenges FTC’s Report on Pharmacy Benefit Managers, Alleging Unconstitutional Actions and Misleading Claims
Cigna, FTC, Pharmacy Benefit Managers (PBMs), Express Scripts, Unconstitutional Report, Misleading Claims, Drug Prices, Healthcare System
HPV-Based Cervical Cancer Screening: Insights into Sample Preference and Cost-Effectiveness
HPV testing, Cervical cancer screening, Sample preference, Cost-effectiveness, Screening guidelines
Cigna’s Express Scripts Files Lawsuit Against FTC Over Allegedly Biased PBM Report
Express Scripts, FTC, PBM Report, Lawsuit, Biased, Erroneous, Drug Prices, Healthcare
AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefit in Muscle-Invasive Bladder Cancer, Raises Questions on FDA Approval for Perioperative Design
AstraZeneca, Imfinzi, durvalumab, muscle-invasive bladder cancer, MIBC, perioperative trial design, FDA approval, survival benefit
Enhertu Demonstrates Promising Efficacy in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases
Enhertu, Trastuzumab Deruxtecan, HER2-positive metastatic breast cancer, brain metastases, progression-free survival, objective response rate.